| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 8, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2020, the independent...
-
Jan 7, 2020- Curis to initiate Phase 1a/1b study for CI-8993 in 2020 -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and...
-
Dec 6, 2019- Preliminary clinical data on CA-4948 demonstrates anti-cancer activity and favorable safety profile -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing...
-
Dec 6, 2019- 11 patients enrolled to-date in Phase 1 study; combination has been generally well-tolerated -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its...
-
Nov 26, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...